https://scholars.lib.ntu.edu.tw/handle/123456789/637423
標題: | Serum RNase L levels in patients with chronic hepatitis B virus infection | 作者: | CHI-LING CHEN TAI-CHUNG TSENG CHUN-JEN LIU JIA-HORNG KAO PEI-JER CHEN WEI-SHIUNG YANG |
關鍵字: | hepatitis B virus | innate immunity | RNase L | 公開日期: | 2024 | 卷: | 54 | 期: | 3 | 起(迄)頁: | 244 | 來源出版物: | Hepatology Research | 摘要: | Background/Aims: Chronic hepatitis B virus (HBV) infection still poses a major threat to global health. Oligoadenylate synthetase–ribonuclease L (RNase L) antiviral pathway is one of interferon-induced antiviral effectors. The relationship between RNase L and HBV has never been investigated and we aim to examine the serum RNase L levels in patients with different stages of chronic HBV infection. Methods: The patients were enrolled from 1985 to 2000, who had been HBsAg positive for longer than 6 months, at the National Taiwan University Hospital. In total, 426 patients with chronic HBV infection were included in this study, including 135 inactive carriers, 148 cirrhosis, and 143 hepatocellular carcinoma (HCC) cases. Results: The RNase L levels increase as the disease severity increases. Higher RNase L levels were associated with higher HBV viral load, and the HBV-RNase L relationship was replaced by the disease severity status when adding disease status into the model. Compared with inactive carriers, the risk of liver cirrhosis was 60-fold (odds ratio = 60.8, 95% confidence interval = 3.49–1061) with the highest quintile of RNase L levels, after the adjustment of HBV DNA. The dose–response trend was statistically significant with quintiles and one increment of RNase L level in relation to liver cirrhosis. Similar results were found when HCC was compared with inactive carriers, while there was no association when compared between liver cirrhosis and HCC. Conclusions: A positive relationship between serum RNase L and HBV viral titers or advanced disease status is uncovered in this study. Further investigation in this area may provide more details of an innate immune response for HBV and opportunity for novel therapeutic strategy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/637423 | ISSN: | 13866346 | DOI: | 10.1111/hepr.13977 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。